European journal of gastroenterology & hepatology
Cure8 research brief
Why This Matters
People with IBD and a recent solid cancer face a trade-off between controlling IBD with advanced therapies (biologics or small molecules) and potential oncologic or infectious risks. This study examined real-world outcomes to help inform that balance.
The main takeaway is that after accounting for timing bias, mortality was similar but hospitalizations, steroid use, and serious infections were higher with advanced therapy.
Who Should Pay Attention
Adults with IBD and recent solid malignancy, clinicians (gastroenterologists and oncologists), and researchers studying immunosuppression after cancer
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The study used a large electronic-health-record database and propensity matching to reduce confounding, but the authors note that residual confounding and immortal time bias can affect results. The landmark analysis was intended to address timing-related bias and changed some findings, underscoring how analytic choices influence conclusions.
Decisions about starting or continuing biologics/small molecules after recent cancer remain individualized and are best made in multidisciplinary teams including oncology and gastroenterology.
Keep In Mind
Source is an abstract from a peer-reviewed journal reporting a retrospective cohort analysis using TriNetX EHR data. Observational designs can be influenced by immortal time bias and confounding by indication; the authors used propensity matching and a 6-month landmark analysis to address these issues.
This summary is grounded in the article abstract and does not represent a full review of the complete study.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationEuropean journal of gastroenterology & hepatology
AuthorsAlvina F, Aloysius MM, Chaar A +1 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedOct 20, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Predictors of ustekinumab intensified dose escalation in inflammatory bowel disease: a real-world (UST-predict) study
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study
This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...
Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...